154 related articles for article (PubMed ID: 17503465)
1. Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells.
Poincloux R; Cougoule C; Daubon T; Maridonneau-Parini I; Le Cabec V
J Cell Physiol; 2007 Oct; 213(1):212-20. PubMed ID: 17503465
[TBL] [Abstract][Full Text] [Related]
2. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
3. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
4. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
5. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
7. Re-arrangements of podosome structures are observed when Hck is activated in myeloid cells.
Poincloux R; Vincent C; Labrousse A; Castandet J; Rigo M; Cougoule C; Bordier C; Le Cabec V; Maridonneau-Parini I
Eur J Cell Biol; 2006 Apr; 85(3-4):327-32. PubMed ID: 16546576
[TBL] [Abstract][Full Text] [Related]
8. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Klejman A; Schreiner SJ; Nieborowska-Skorska M; Slupianek A; Wilson M; Smithgall TE; Skorski T
EMBO J; 2002 Nov; 21(21):5766-74. PubMed ID: 12411494
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.
Jacobberger JW; Sramkoski RM; Frisa PS; Ye PP; Gottlieb MA; Hedley DW; Shankey TV; Smith BL; Paniagua M; Goolsby CL
Cytometry A; 2003 Aug; 54(2):75-88. PubMed ID: 12879454
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
11. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
12. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
Pene-Dumitrescu T; Peterson LF; Donato NJ; Smithgall TE
Oncogene; 2008 Nov; 27(56):7055-69. PubMed ID: 18794796
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
14. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
16. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains.
Stanglmaier M; Warmuth M; Kleinlein I; Reis S; Hallek M
Leukemia; 2003 Feb; 17(2):283-9. PubMed ID: 12592324
[TBL] [Abstract][Full Text] [Related]
17. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
[TBL] [Abstract][Full Text] [Related]
18. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
19. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms.
Poincloux R; Al Saati T; Maridonneau-Parini I; Le Cabec V
Eur J Cancer; 2009 Feb; 45(3):321-7. PubMed ID: 19114024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
